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Nearly all individuals with Down Syndrome (DS) display pathology associated with Alzheimer’s disease (AD)
beginning as early as age 30. Previous research in typically developed adults suggests that increased moderate-tovigorous physical activity (MVPA) may improve cognitive function and protect against age-related structural and
functional changes in the brain; however, the potential impact of increased MVPA on the development of AD in
adults with DS has not been evaluated. Despite the potential positive impact of MVPA on cognition and AD risk,
participation in MVPA among young adults with DS is low. The limited research evaluating strategies for
increasing MVPA in adults with DS has been unsuccessful in increasing MVPA. Results from our preliminary
investigation where we remotely delivered real-time MVPA, led by a trained health educator, to groups of adults
with DS in their homes via video conferencing on a tablet computer demonstrated high attendance, increased
MVPA during group sessions, and improvements in cognitive function. However, the sustainability, impact on
total daily MVPA, optimal session frequency, and potential impacts on cognitive function and brain health of
remotely delivered group MVPA sessions in adults with DS are unknown. Therefore, we will conduct a trial in 80
non-demented adults with DS to determine the feasibility and potential efficacy of remotely delivered group
MVPA sessions to increase daily MVPA, relative to a usual care control. Secondarily we will assess the impact of
MVPA on cardiovascular fitness, quality of life, cognitive function and brain parameters related to AD.
NCT registration: NCT04048759.

1. Introduction
Down syndrome (DS) or trisomy 21 is the most common chromo
somal abnormality which has impact both during childhood and later on
in adult life leading to an intellectual and development disability (IDD)
[1]. The number of people with Down Syndrome (DS) living the US has
grown from ~50,000 to ~250,700 over the past 70 yrs [2]. Nearly all

individuals with DS display pathology associated with Alzheimer’s dis
ease (AD) beginning as early as age 30 [3,4]. Previous research suggests
that increased moderate-to-vigorous physical activity (MVPA) may
improve cognitive function and may prevent or delay the development
of dementia in adults without DS [5–8]; however, the potential impact of
increased MVPA on the development of AD in adults with DS has not
been evaluated.

Abbreviations: MVPA, moderate to vigorous physical activity; DS, Down Syndrome; AD, Alzheimer’s Disease; RL, remote low; RH, remote high; UC, Usual Care.
* Corresponding author. University of Kansas Medical Center, Department of Internal Medicine, 3901 Rainbow Blvd, Mail Stop 1073, Kansas City, KS, 66160, USA.
E-mail addresses: lptomey@kumc.edu (L.T. Ptomey), aszabo@kumc.edu (A.N. Szabo-Reed), lmartin2@kumc.edu (L.E. Martin), mmayo@kumc.edu (M.S. Mayo),
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functional connectivity, structural connectivity, cerebral blood flow),
and 2) determine the feasibility (retention, session attendance, use of
recorded sessions (RH/RL only)) and safety of RL, RH, and UC arms. The
results of this trial will determine the feasibility and potential effec
tiveness of the RL, RH, and UC interventions on MVPA, and gather initial
estimates of the impact of MVPA on cognition and brain parameters
related to AD in adults with DS. This information is required to inform
the development of adequately powered, late stage confirmatory trials
to evaluate the role of increased MVPA to prevent or delay AD in adults
with DS.

Despite the potential positive impact of MVPA on cognition and AD
risk, participation in MVPA among young adults with DS is low. Reports
suggest that ~9% of adults with IDD, including DS, meet the current
150 min/wk public heath recommendation for MVPA [9,10]. The
limited research evaluating intervention strategies for increasing MVPA
in adults with DS includes adults with all IDDs and has been unsuccessful
in increasing short-term (�12 wks) or long-term MVPA (18 mo)
[11–13].
Adults with DS face numerous barriers to participation in MVPA
including lack of appropriate options and educational materials relative
to physical activity, lack of self-confidence to exercise with typically
developed peers, lack of social support, poor motor skills, and issues
relative to financial burden and transportation [14,15]. Our group
recently developed and conducted a preliminary investigation of a
remote method which delivers real-time MVPA, led by a trained health
educator, to groups of adults with DS in their homes, via video confer
encing on a tablet computer [16,17]. This approach eliminates the need
for transportation, provides social interaction and support from both the
health educator and other participants, and requires minimal care
giver/staff involvement. In our preliminary 12-wk. trial, 27 young
adults with DS were randomized to 1 or 2, remotely delivered group
MVPA sessions/wk. lasting 30 min each. Participants were asked to
complete MVPA outside of the group sessions, and to attend weekly
30-min video chat sessions designed to support intervention compliance.
All participants completed the 12-wk. intervention. Attendance at group
sessions was high and did not differ between groups (1 session/wk. ¼
90%; 2 sessions/wk. ¼ 89%). As expected, MVPA obtained during group
sessions was higher in participants in the 2 session/wk. (57.7 � 15.3
min/wk) compared with the 1 session/wk. group (26.6 � 3.0 min/wk).
Participants in both groups showed improvements in working memory,
attention and reaction time as assessed by the CANTAB® battery for DS.
The results of our pilot were encouraging; however, the sustain
ability, impact on total daily MVPA, optimal session frequency, and
potential impacts on cognitive function of remotely delivered group
MVPA sessions in adults with DS is unknown. This led to the develop
ment of the current randomized trial in adults with DS designed to
determine the feasibility and potential efficacy of remotely delivered
group MVPA delivered at two different frequencies to increase daily
MVPA, relative to a usual care control.

2.2. Theoretical model
The proposed intervention is based on Social Cognitive Theory [18].
Specifically, we will employ participant goal setting (weekly MVPA
goals), self-monitoring of MVPA (Fitbit), stimulus control (strategies to
decrease cues for less desirable, and increase cues for more desirable
physical activity behaviors), prompts (iPad calendar reminders),
scheduling time for MVPA, environmental cues, modeling (by other
participants), positive reinforcement/social support (group session
leader, caregiver/study partner, other participants), and other
self-regulatory techniques in both intervention arms. Social support [14,
15,19], caregiver support [20,21], self-efficacy for exercise [14], and
motor fitness [22] have all been associated with higher levels of physical
activity in individuals with DS and IDD.
2.3. Participant eligibility
Primary care physician (PCP) clearance will be required for all par
ticipants. To enhance generalizability, individuals on medications for
common chronic diseases, i.e., depression, blood pressure, lipids, type 2
diabetes, and those with previous congenital heart defects will not be
excluded. Inclusion/Exclusion criteria are presented in Table 2.
Recruitment/Randomization. Project staff will contact local com
munity agencies serving adults with DS, case managers, and Community
Developmental Disabilities Organizations (CDDOs) by mail/email, pro
vide presentations at CDDO meetings, and text for CDDO newsletters
describing the project. Interested parents/guardians, caregivers, or
adults with DS will be asked to contact the study coordinator via email,
our website, or a dedicated toll-free study phone number that will be
included in all recruitment materials. The study coordinator will contact

2. Methods and materials
2.1. Overview of study design (Table 1)

Table 1
Design overview for the 12-month physical activity intervention in adults with
down syndrome.

Eighty non-demented adults with DS will be randomized to a 12-mo.
trial to compare changes in daily MVPA will assessed by portable
accelerometer (ActiGraph wGT3XBT, ArchiMed Co, Lyon, AuvergneRhone-Alpes, France). Adults with DS will be randomized (2:2:1) to
attend 40 min remotely delivered group MVPA sessions (Zoom™ Video
Conferencing Inc., San Jose, CA) at a low frequency (1 session/wk., RL)
or high frequency (3 sessions/wk., RH), or a usual care control (UC). All
participants will be given an iPad tablet computer (Apple Inc, Cupertino,
CA and a step counter (Versa Lite™, Fitbit, San Francisco, CA). Partic
ipants in both the RL and RH arms will receive weekly group MVPA
sessions, access to resources for increasing MVPA, and twice monthly
remotely delivered (FaceTime®) individual support/education sessions.
Content for both the RL and RH arms will be identical with the exception
of group MVPA session frequency (1 vs. 3/wk.). Participants in the UC
arm, access to resources for increasing MVPA, and twice monthly
(FaceTime®) individual support/education. The primary aim is to assess
daily MVPA (min) in the RL, RH, and UC arms assessed at baseline, 3, 6,
9, and 12 mos, and obtain effect sizes for change in MVPA over 12-mos.
All secondary outcomes will be assessed at baseline, 6 and 12 mos.
Secondary aims will: 1) Assess the impact of MVPA across the RL, RH,
and UC arms on cardiovascular fitness, quality of life, cognitive function
and brain parameters related to AD (whole and regional brain volume,

Intervention Arms

MVPA
recommendation
Group MVPA sessions
Delivery format
Frequency
Intensity
Duration
Content
Access to PA resources
MVPA Self-monitoring
Education/support/
feedback sessions
Participants
Frequency
Delivery format
Duration

Remote High
(RH)

Remote Low
(RL)

Usual Care
(UC)

150 min/wk.

150 min/wk.

150 min/wk.

Yes
Zoom™ video
conferencing
3 d/wk.
�3 METS
40 min
Stretch/aerobic
activity/RE
Yes
Fitbit
Yes

Yes
Zoom™ video
conferencing
1 d/wk.
�3 METS
40 min
Stretch/aerobic
activity/RE
Yes
Fitbit
Yes

No
NA

DS adult þ Study
Partner
2x/mo.
FaceTime®
20 min/session

DS adult þ Study
Partner
2x/mo.
FaceTime®
20 min/session

DS adult þ
Study Partner
2x/mo.
FaceTime®
20 min/session

Note: NA ¼ not applicable, RE ¼ resistance exercise.
2

NA
NA
NA
NA
Yes
Fitbit
Yes
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support session (all groups) providing opportunities for increased
MVPA, and assisting with self-monitoring of MVPA.

Table 2
Participant eligibility criteria for a 12-month physical activity intervention in
adults with down syndrome.

2.3.1. Intervention components

Inclusion
Residential Status:
Age:
Diagnosis:
Ambulatory:
Health status:
Communication:
Internet:

Living at home with a parent/guardian or in a supported
living environment with a caregiver who agrees to serve as
a study partner.
�18 years
Down Syndrome
Must be able to participate in physical activity and walk 10
feet unassisted.
Must provide physician clearance to participate.
Sufficient functional ability to understand directions,
communicate preferences, wants, and needs through
spoken language
Internet access in the home

2.3.1.1. MVPA recommendations. We will target 150 min/wk of MVPA
(�3 METs) for all groups as recommended for all adults by the American
College of Sports Medicine [33] and the U.S. Department of Health and
Human Services [34]. MVPA recommendations will progress from 60
min/wk (3 d/wk, 20 min/d) to 150 min/wk (5 d/wk, 30 min/d) at the
beginning of mo. 4 and remain at 150 min/wk through the end of the
study. Accumulated MVPA in bouts �10 min will be permitted.
2.3.1.2. MVPA self-monitoring. Participants in all 3 groups will be asked
to wear a Fitbit Versa Lite activity tracker on their non-dominant wrist
over the duration of the 12-mo. trial. This request may appear onerous;
however, wearing the Fitbit is akin to wearing a wristwatch. Real-time
data from the Fitbit is automatically transferred, via the web, to cloud
storage (Fitabase, Small Steps Labs LLC, San Diego, CA), thus participant
burden is minimal. Immediate participant feedback via a graphic display
of daily steps, minutes of sedentary time, time spent in light, moderate
and vigorous PA will be available on the iPad. This data, accessible to
health educators, will be used only to provide motivation and feedback
during the education/support sessions. Outcome data for MVPA will be
assessed by accelerometer as described subsequently. Participants will
be reminded to wear and charge the Fitbit during the individual sup
port/education sessions, and will receive automatic reminder messages
via the iPad using the iCal app.

Exclusion
Dementia:

Diagnosis of dementia as determine by the Dementia
Screening Questionnaire for Individuals with Intellectual
Disabilities (DSQIID) [23]

Health concerns:

Serious medical risk, such as cancer, recent cardiac event, i.
e., heart attack, stroke, angioplasty, or cannot participate in
physical activity.
Pregnancy during the previous 6 mos, currently lactating or
planned pregnancy in the following 24 mos. Participants
who become pregnant will be removed from the study and
referred to appropriate agencies for consultation.
Participation in a regular exercise program, i.e. � 20 min/d
� 3 d/wk.

Pregnancy:

Physical Activity
Level:

the interested individuals by phone to answer questions and conduct an
initial eligibility screen. Home visits will be scheduled with those
remaining interested, and potentially eligible, to obtain informed con
sent (participants or legal guardian) and participant assent (if not their
own legal guardian) and determine final eligibility based on the DSQIID
scores. Project staff will send a form (fax/email) to the potential par
ticipant’s PCP which describes the study and requests clearance for
participation. Participants found to be ineligible will be provided with
written materials describing available resources for increasing physical
activity. Cohorts of ~10–20 participants will be recruited, and computer
randomized. Participants will be stratified by sex and age (18–30 or
>30) and then sequentially randomized by the study statistician with
2:2:1 allocation to the RL, RH, and UC arms. This randomization scheme
was selected to include more participants in the group video confer
encing arms which, if successful, will be included in a later stage trial
examining the effectiveness of increased MVPA using the video confer
encing approach on cognitive function and brain health in adults with
DS. Intervention assignments will be concealed in envelopes and deliv
ered to the study coordinator.
Caregiver role. Caregivers play a potentially pivotal role for lifestyle
change in adults with DS, e.g., assisting with scheduling and participa
tion in appropriate physical activity [24]. Caregivers have been included
in successful lifestyle interventions by our group [12,17,25] and others
[26–28]. However, the limited data on the impact of caregiver support
on MVPA in individuals with DS provide conflicting results [29,30]. No
clear guidance on how best to involve caregivers in interventions is
available [31]. Adults with IDD, including DS, frequently live with a
paid caregiver, and turnover among paid caregivers is high [32]. In our
previous 18-mo. weight management trial in adults with IDD
(DK38359) ~ 74% of participants had a paid caregiver, and ~39% had 2
or more study-specific caregivers across 18 mos. For this current trial,
we will recruit either a parent/guardian or residential support staff to
serve as a study partner for each participant. Study partners will be
allowed to assist multiple adults, provided all adults are in the same
intervention group. Study partners will be asked to attend all individual
support/education sessions, and to support, encourage, and assist par
ticipants in complying with the study protocol, such as reminding them
to attend the group exercise sessions (RL and RH only), individual

2.3.1.3. RL and RH intervention. Orientation. Each participant and their
study partner will be asked to attend an orientation session (~60 min)
conducted at the University of Kansas Medical center and led by their
health educator. In addition to describing study requirements and
distributing iPads, Fitbits, resistance bands, etc., this meeting is
designed to establish rapport between the health educator and partici
pants prior to initiating the group video conference sessions. The health
educator will describe and demonstrate the Zoom™ software and the
Fitbit and will allow time for practice and questions. Additionally, basic
stretching exercises, the use of the resistance bands, and simple dance
movements will be demonstrated and practiced.
Group exercise sessions-Delivery. All MVPA sessions will be conducted
by a health educator experienced in working with individuals with DS
and supervised by the principal investigator. Group sessions will be
delivered using an iPad tablet computer provided to all participants. The
iPad will be pre-loaded with video-conferencing software (Zoom™)
which allows participation by multiple users. Participants will be pro
vided with an iPad/HDMI adaptor, which allows video conference ses
sions to be displayed on a larger TV screen, if desired. Tutorials
describing troubleshooting for common technical problems, e.g.,
internet connectivity etc., will be loaded on the iPad. Participants with
technical issues during the intervention can also contact research staff
by phone or email. Access to non-study related materials, e.g., web
browsing, app store, etc., will be blocked on all iPads. The iPads for both
groups will also be pre-loaded with the Fitbit application.
Group exercise sessions-Schedule. Group exercise sessions will be
scheduled between 10 a.m. and 7 p.m., 3 days/wk. for RH and 1 day/wk.
for RL. This time window was selected based on the preference of par
ticipants in our 12-wk pilot trial in individuals with DS. Prompts
reminding participants of upcoming sessions will be sent via the iPad.
The same health educator will conduct MVPA sessions for both the RH
and RL groups in each cohort to minimize health educator effects.
Group exercise sessions-Content. Each session will include a warm-up
(~5 min), moderate-to-vigorous intensity aerobic and resistance exer
cise (~30 min), and cool-down/stretching (~5 min). Resistance exercise
may be especially relevant, as adults with DS have reduced muscle
3

L.T. Ptomey et al.

Contemporary Clinical Trials Communications 19 (2020) 100607

strength compared with their typically developing peers [35]. The aer
obic/resistance exercises, accompanied by music, will include wal
king/jogging in place, dancing, imitating animal movements,
vertical/horizontal jumps, squats, and Thera-Band exercises for major
muscle groups. Activities will be modified for participants having dif
ficulty with specific movements. The intensity of the initial sessions, as
determined by Fitbit, will be light-to-moderate, with intensity
increasing to moderate-to-vigorous at ~6 wks. All participants will be
able to see, hear, and speak to each other during the group sessions.
During each session, health educators will encourage interactions be
tween participants in support of their peer’s efforts to increase MVPA
and provide participant feedback relative to their level of weekly MVPA
as assessed by the Fitbit. As the intervention progresses, participants will
be asked to volunteer to create and lead the group in a brief (3–5 min)
exercise bout. Participants will also be encouraged to interact with each
other by providing verbal support to each other (“great job”, “keep it
up”), performing activities such as tossing an imaginary ball to other
participants, or challenging other participants to complete a skill such as
10 hops on one leg etc. All group sessions will be video recorded.
Homework assignments. The group exercise sessions have the poten
tial to provide 30 min/wk of MVPA for the RL group and 90 min/wk for
the RH group. Thus, MVPA outside these sessions will be required to
meet the 150 min weekly recommendations. Health educators in the RH
and RL groups will provide weekly challenges in the form of meeting a
goal for increased steps, trying a new activity, or creating and per
forming their own exercise routine etc. Participants will be provided
access to video recordings of all group exercise sessions that can be
followed on their own to help in meeting weekly MVPA goals across the
12-mo. trial, if desired. Recordings will be sent to Dropbox and will be
accessible to participants on the iPad. We will also provide information
regarding increasing physical activity, available from the National
Center on Health, Physical Activity and Disability (NCHPAD) and the
Special Olympic athletes home training guide. Participants will be asked
to document MVPA outside group sessions using the Fitbit. Participants
will be asked to press a button on the Fitbit at the beginning and end of
each group exercise session which will allow us to differentiate MVPA
obtained during group sessions from other daily MVPA.
Education/support sessions. Twice monthly 20-min. education/sup
port sessions will be delivered to participants and their study partners
remotely on the iPad using FaceTime®. These sessions, led by the health
educator, will be designed to educate and support participants with
meeting their 150 min/wk. MVPA goal. Each session will include a re
view of MVPA self-monitoring data, goal setting, strategies to increase
and support MVPA, and discussion of a topic relevant to MVPA
including: the importance of MVPA for health and function, how to
include MVPA in the daily schedule, reducing barriers to MVPA,
appropriate types of activity, creating a safe environment for MVPA,
alternative activities for inclement weather, importance of hydration,
etc. Session outlines and materials will be preloaded on the iPad where
they can be accessed by participants at any time.

education/support sessions, identical to the education/support sessions
provided in the RL and RH arms, described above, will be delivered to
participants and their study partners remotely on the iPad using Face
Time® Session outlines and materials will be preloaded on the iPad
where they can be accessed by the participant at any time.
2.4. Health educator training
We currently have 3 health educators with experience in delivering
group exercise and individual education and support using video
conferencing to groups of adults with DS. If needed, new health edu
cators will be trained by the principal investigator and will shadow an
experienced health educator for a minimum of 3 mos prior to delivering
the intervention on their own. The principal investigator will conduct
weekly meetings with all health educators to discuss issues relative to
intervention delivery. Study staff will review recordings from all
scheduled group MVPA and individual support sessions. The content
delivered will be compared with a checklist of scheduled activities/
topics. Feedback will be provided to all health educators; those covering
<80% of scheduled activities/topics will receive additional training and
will be dismissed if the problem recurs.
2.5. Participant incentives
Reinforcement systems, known as positive behavioral support pro
grams, have been successful in promoting behavioral change in in
dividuals with DS [36]. These strategies provide modest incentives to
motivate participants to meet their goals, and were successfully used in
our previous trials that included adults with DS [12,13,17]. Participants
in all groups who complete self-monitoring of MVPA on 5 of 7 d/wk will
receive an electronic star. The allowance iPad app, Rooster Money
(Rooster Money LLC, London, England), will be used to distribute stars
to participants. Participants will get a notification on their iPad every
time they receive a star. Participants will receive $10 each time they
obtain 10 stars. Additionally, to compensate for time and travel, par
ticipants will receive $150 for completion of each of the 3 outcome
assessment laboratory visits (baseline, 6, 12 mos), and $50 for
completion of the additional two accelerometer outcome collection
periods (3 and 9 mos). As an additional incentive, participants will be
allowed to keep the iPad and Fitbit on completion of the trial (12 mos).
2.5.1. Outcome assessments
With the exception of assessment of daily MVPA by accelerometer,
all outcomes will be assessed at the University of Kansas Medical Center,
in Kansas City, KS. Cognitive function, cardiovascular fitness, and
quality of life will be assessed at the Center for Physical Activity and
Weight Management and all neuroimaging outcomes will be assessed at
Hoglund Biomedical Imaging Center The primary outcome, daily total
MVPA will be assessed at baseline, 3, 6, and 12 mos. All secondary and
descriptive outcomes (height weight waist circumference) outcomes will
be assessed at baseline, 6 and 12 mos.

2.3.1.4. Usual care (UC) intervention. Orientation. Participants and their
study partner will be asked to attend an orientation session (~60 min)
conducted at the University of Kansas Medical center and led by their
health educator. Like the RL and RH groups, the orientation will be used
to described study requirements and distribute iPads and Fitbits. The
health educator will describe and demonstrate the FaceTime® software
and the Fitbit and will allow time for practice and questions.
Intervention. The UC intervention will follow the traditional approach
to promote increased MVPA in individuals with DS previously used by
our group [12,13,25] and others [11,27]. Participants will receive an
iPad tablet loaded with information regarding increasing MVPA avail
able from NCHPAD and the Special Olympic athletes home training
guide and will also receive resistance bands and a Fitbit for
self-monitoring MVPA (described below). Twice monthly 20-min.

2.5.1.1. Primary outcome. MVPA will be assessed using an ActiGraph
wGT3XBT tri-axial accelerometer. The ActiGraph provides valid and
reliable assessments of physical activity in typically developed adults
[37–39], and has been widely used to describe physical activity levels in
adults with DS [40,41]. Participants will be asked to wear the ActiGraph
on a belt over the non-dominant hip at the anterior axillary line during
waking hours for 7 consecutive days, with the exception of bathing,
swimming, and contact sports. A 7-day monitoring period provides a
reliable estimate of MVPA [42,43]. The hip rather than the wrist loca
tion will be used due to the lack of comparable data and established
protocols for assessment of MVPA using wrist-worn ActiGraphs [44].
Research staff will distribute and demonstrate proper placement of the
ActiGraphs at laboratory visits scheduled at baseline 6, and 12 mos.
4
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ActiGraphs will be distributed by mail for the 3, 9 mo assessments.
ActiGraphs will be returned by postage paid mail following completion
of all assessments. Daily reminders to comply with the ActiGraph pro
tocol will be sent to participants’ iPads each morning during the 7-day
monitoring period. ActiGraphs will be initialized and downloaded
using ActiLife Software version 6.13.3 or higher (ArchiMed Co, Lyon,
Auvergne-Rhone-Alpes, France) and set to collect in the raw data mode
from all 3 axes at 60 Hz. Accelerometer data will be processed using the
protocol for adults used in the 2003–2004 and 2005–2006 cycles of
NHANES [45,46]. Data will be aggregated over 60-sec epochs. The
following intensity cut-points will be used: sedentary (<1.0 MET; � 100
counts/min), light (1.1–2.99 METs; 101–2019 counts/min.), moderate
(3.0–5.99 METs; 2020–5988 counts/min) and vigorous � 6 METs; �
5999 counts/min) [45,46]. Non-wear time will be defined as at least 60
consecutive minutes of zero counts, with allowance for 1–2 min of
counts between 0 and 100. Counts �20,000/min will be considered
spurious [47]. All accelerometer data processing will be completed
using custom SAS/R programs developed by our team.

standard of living, health, life achievement, personal relationships,
personal safety, community-connectedness, and future security. Cron
bach alpha of 0.76, and 1- to 2-wk. test–retest reliability of 0.58 have
been reported in adults with IDD [60]. The PWI-ID scale differs from the
original Personal Well-Being Index (PWI-A) in that it incorporates a
pre-testing protocol to determine whether, and to what level of
complexity, respondents are able to use the scale. The ID version also
uses more simple and concrete wording. An additional question which
asks how happy or sad the respondent is with life as a whole is included.
A reduced choice format, illustrated as a series of outline faces, from
very sad to happy, is provided to enhance comprehension and sub
stitutes for the Likert scale used in the PWI-A version [61].
Neuroimaging. Neuroimaging measures will include: brain volume (i.
e. structural MRI), functional connectivity (i.e. resting state fMRI
(rsfMRI)), structural connectivity (i.e. diffusion tensor imaging (DTI)),
and blood flow (i.e. arterial spin labeling (ASL)). We will utilize the scan
sequences similar to those implemented by the NIAD and NIH funded
Alzheimer’s Biomarkers Consortium- Down Syndrome (ABC-DS) and
currently used in the IGNITE (Trial [62] examining cognitive changes
related to exercise in aging. Scanning will be performed on a 3-T
Siemens Skyra scanner (Siemens, Erlangen, Germany) fitted with a
20-channel head coil. Following automated scout image acquisition and
shimming procedures to optimize field homogeneity, structural, rsfMRI,
DTI, and ASL data will be acquired. Participants will be able terminate
the scan at any time during the procedure. Participants who fail to
complete the baseline scan, will not be asked to complete subsequent
scans at 6 or 12 mos. The structural scan will consist of T1-weighted MRI
(3D MPRAGE sequence, TR/TE ¼ 2400/2.31 ms, field of view ¼ 240 �
256 mm2, 0.8 mm isotropic resolution, 224 slices). Structural MRI im
aging has elucidated the specific brain regions impacted by dementia in
DS. These grey matter changes are detectable prior to the development
of signs of clinical dementia [63,64] and have been impacted by car
diovascular fitness/MVPA(7). Functional and anatomic images obtained
in each session will be aligned and normalized to a DS brain template
[65]. Volumetric analyses of overall and regional, e.g. hippocampus,
brain volumes will be performed using FreeSurfer segmentation using
the longitudinal processing stream. Resting state fMRI will be performed
using a gradient echo multiband EPI sequence (TR/TE ¼ 1000/40 ms,
multiband factor ¼ 8, slice thickness ¼ 2.5 mm, in plane resolution ¼
2.5 mm, 64 slices, 480 measurements) [66–68]. rsFMRI examines
functional connectivity within and between brain networks. Individuals
with DS show increased connectivity between networks compared to
typically developing adults which has been hypothesized to reflect
increased compensatory brain activation [65]. Pre-processing of rsfMRI
data will be performed for each participant using Analysis of Functional
NeuroImages (AFNI, Medical College of Wisconsin). The rsfMRI images
will be realigned to the first slice collected in each scanning session to
correct for motion. The images will be spatially smoothed with a 4 mm
Full Width Half Maximum (FWHM) Gaussian blur. DTI examines
structural connectivity by assessing the integrity of white matter tracks.
The DTI scanning parameters include diffusion weighted acquisition in
64 gradient directions (TR/TE ¼ 3050/119.4 ms, multiband factor ¼ 4,
slice thickness ¼ 2.5 mm, in plane resolution ¼ 2.5 mm, b-values of 0,
1500, 3000 s/mm2) [66–68]. DTI analysis will be conducted in AFNI
[69] and TORTOISE version 3.2 [70,71]. Processing steps will include
eddy current correction modeled with quadratic functions; motion
distortion correction; and EPI distortion correction using
blip-up/blip-down estimation with DR-BUDDI [72]. Output metrics will
include fractional anisotropy (FA), trace maps (TR) and mean diffusivity
(MD). A pseudo-continuous ASL sequence [73,74] will be collected to
measure changes in blood flow that may be related to increased fitness
associated with physical activity. PCASL scanning parameters will
include 20 vol of 48 axial slices (TR/TE ¼ 4300/22.42 ms, slice thick
ness ¼ 2.5 mm, in plane resolution ¼ 3.1 mm, 4 segment readout). ASL
analyses will be performed using the USC Laboratory of Functional MRI
Technology (LOFT) CBF Preprocess and Quantify packages [75], and the

2.5.1.2. Secondary outcomes. Cognitive Function. Working memory,
processing speed, multitasking, and episodic memory will be assessed
using tests selected from the widely used Cambridge Neuropsychologi
cal Test Automated Battery (CANTAB®, Cambridge Cognition, LTD,
Cambridge, UK) [48–50]. These standardized tests have been exten
sively evaluated, provide normative data, and allow for comparisons
across trials. CANTAB® tests have acceptable construct [51,52] and
concurrent validity [52]. Specifically, we will use the CANTAB® DS
Battery which has been used in previous trials in individuals with DS
[53,54] including our pilot trial [16]. The tests in this battery, which
include measures of multitasking, episodic memory, executive function,
working memory, and processing speed, have demonstrated sensitivity
to disease-specific cognitive deficits in DS, including those related to
hippocampal and frontal lobe dysfunction [55] and are also sensitive to
the changes in cognitive function seen in AD [56]. All tests will be
administered in a quiet room on an iPad following manufacturer’s in
structions. Tests will be administered in a random order and scored by a
co-investigator who will be blinded to intervention group.
Cardiovascular fitness. Cardiovascular fitness is associated with brain
volumes in the medial, temporal, and parietal cortices, suggesting that
increasing cardiorespiratory fitness, by increased MVPA, may modify
AD-related brain atrophy [7,8]. Cardiovascular fitness will be assessed
using a maximal treadmill test, which are commonly used in adults with
DS [22,57] using the protocol of Fernhall et al. [58]. The protocol starts
with a 2-min warm-up at 0% grade at a comfortable walking speed. After
the warm-up, the speed will be adjusted to a individualized brisk
walking speed. After 2 min of walking at a brisk speed and 0% grade, the
grade will increase every 2 min by 2.5% until a 12.5% grade is reached.
From that point, grade will be held constant, whereas speed will be
increased by 1.6 or 0.8 km h 1 every minute until exhaustion. Heart rate
(Polar RS 400) and expired O2 and CO2 (ParvoMedics TrueOne 2300 calibrated prior to each test) will be measured in 20 s intervals. The test
will be terminated when participants achieve two or more of the
following four criteria of peak effort: 1) volitional exhaustion, 2)VO2 or
HR plateau with an increase in work rate (VO2 plateau defined as an
increase less than 150 mL min 1; HR plateau defined as an increase less
than 2 bpm), 3) HRpeak within 5 beats of predicted HRpeak according to
the formulas of Fernhall et al. [58], and 4) an RER �1.0. The exercise
test will be terminated early if the participants are unable to maintain
the treadmill speed or requests that the test be stopped. A cardiologist
will be on-site for all treadmill tests per American College of Sports
Medicine recommendations for testing individuals with DS [59] and
ECG will be monitored continuously.
Quality of Life. Quality of life will be assessed with the Personal WellBeing Index-Intellectual Disability (PWI-ID) [60,61]. This instrument
contains 7 items, each corresponding to a quality of life domain:
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ASL Data Processing Toolbox (ASLtbx) [76] with Statistical Parametric
Mapping version 12 software (SPM12) [77], applying methods that are
currently implemented for the Alzheimer’s Disease Center registry at
KUMC. Processing steps will include motion correction, co-registration
to the T1-weighted anatomical image, temporal and spatial filtering,
and tissue segmentation of grey matter, white matter, and cerebrospinal
fluid compartments for partial volume correction.

correlation between baseline MVPA, and MVPA at subsequent time
points, will be � 0.5. Thus, the standard deviation of change in MVPA
will be no greater than the standard deviation of MVPA at a given time
point. Therefore, we would have the same ability to assess and detect a
between group effect for change in MVPA as we stated for detecting a
between group difference in MVPA at given time point, i.e. 10 min/day.
2.8.2. Primary Aim
Our primary aim is to assess total daily MVPA (min.) (exercise ses
sions þ other MVPA) among the RL, RH, and UC arms at baseline, 3, 6, 9,
and 12 mos and obtain effect sizes for change in total daily MVPA over
12-mos. We will calculate the mean and standard deviation and 95%
confidence intervals of total daily MVPA at each time point for all 3
groups, as well as for the change from baseline to each time point. This
descriptive information will be summarized graphically which will aid
in determining if, and when group differences in MVPA arise. The cor
responding effect sizes at each time point will be calculated as the be
tween group differences in the mean divided by the common standard
deviation. We will also estimate the correlation of total daily MVPA over
time within individuals. This information will be critical to identifying
whether single point in time or longitudinal assessments will be utilized
to identify the sample size needed for future large-scale confirmatory
trials. A repeated measures ANOVA will be used to compare between
group changes in MVPA from baseline to each time point (3, 6, 9, 12
mos) using a linear mixed model approach with an autoregressive cor
relation structure over time. The model will include main effects of
group and time and a group by time interaction which will provide an
estimate of the treatment effect when modeling longitudinally. The in
formation on total daily MVPA obtained from this trial will provide solid
preliminary data to determine the potential for an intervention effect
and inform subsequent trials.

2.5.1.3. Descriptive outcomes. Body weight, height and waist circum
ference will be assessed to characterize the study sample. Weight will be
measured in light clothing on a calibrated scale (Model #PS6600, Bel
four, Saukville, WI) to the nearest 0.1 kg. Standing height will be
measured with a portable stadiometer (Model #IP0955, Invicta Plastics
Limited, Leicester, UK). BMI will be calculated as weight (kg)/height
(m2). Waist circumference will be assessed using the procedures
described by Lohman et al. [78].
2.6. Feasibility
Retention. Retention will be measured as the percentage of partici
pants who complete the 12-mo. intervention, defined as completing the
12 mo outcome assessments. Session attendance. Session attendance for
both group MVPA and individual education/support sessions from
baseline to 12 mos will be obtained from records maintained by the
health educator and expressed as the percent of possible sessions.
Attendance at group MVPA sessions will be defined as being logged in to
the video conference and remaining on the screen for the entire 40-min
session (�5 min). Attendance at individual support/education sessions,
for the both exercise and UC conditions, will be defined as answering the
FaceTime® all, and being present on screen for the entire session. Use of
recorded exercise sessions (RL and RH only) will be tracked using Dropbox
which provides information on how many times each user watched part
of a video. Safety. Safety will be measured by number of participants
reporting a serious adverse event, i.e., any untoward medical occurrence
that results in death, is life-threatening, requires inpatient hospitaliza
tion or results in persistent or significant disability/incapacity.

2.8.3. Secondary aim 1
Our first secondary aim will assess the impact of total daily MVPA
across the RL, RH, and UC arms on cardiovascular fitness, quality of life,
cognitive function, and brain parameters (whole and regional brain
volume, functional connectivity, cerebral blood flow) at baseline, 6, and
12 mos. We will estimate the correlation of change in MVPA on changes
in cardiovascular fitness, qualify of life, cognitive function, whole and
regional brain volume, functional connectivity, structural connectivity,
and cerebral blood flow at 6 and 12 mos. This analysis will be completed
with the total sample irrespective of study arm (n ¼ 80).

2.7. Exit interview
Following completion of the 12-mo. intervention, study staff will
conduct structured interviews by phone with a 20% random sample of
participants and study partners from each intervention arm to gather
information that might be useful for improving the intervention. Topics
will include preference for the RH, RL, or UC arms, reasons for missing
scheduled sessions, intervention length, difficulties with compliance,
suggestions for improvements and overall satisfaction with the inter
vention, enjoyment of the MVPA and educational sessions, health edu
cators, MVPA recommendations, satisfaction with the MRI scan
protocol, and willingness to take part in outcome procedures that could
be used in future studies (collection of spinal fluid, PET scan). Qualita
tive content analysis (Atlas, ti 6.2) will be conducted to search for broad
themes across interviews [79].

2.8.4. Secondary aim 2
Our second secondary aim will determine the feasibility (retention,
session attendance, safety, use of recorded sessions (RH/RL only), and
safety) of RL, RH, and UC arms. We will estimate the proportion of
participants retained, session attendance, use of recorded sessions and
safety, i.e. significant adverse events across the 12 -mo. trial, the pro
portion that adhere to treatment within each arm.
2.8.5. Missing data
Missing data is anticipated due to either attrition, e.g., participant
dropout, or nonresponse, e.g., ActiGraph non-wear or malfunction.
Missing data for our primary outcome, total daily MVPA will be
imputed, thus we will not over-recruit at baseline to account for
participant attrition. Missing observations for total daily MVPA will be
handled by Monte Carlo Markov Chain (MCMC) multiple imputation
(MI) [80]. A sufficient number of imputed datasets will be created to
ensure accurate recovery of missing data and analysis results from each
imputed dataset will be combined to make valid statistical inferences.
Our imputation process will incorporate a number of auxiliary variables,
thereby satisfying the missing at random (MAR) assumption [81]. The
state-of-the-science on missing data indicates that FIML and MI are
extremely robust and leads to unbiased generalizability [82]. Addi
tionally, our intent-to-treat approach will employ full information

2.8. Analysis/sample size
2.8.1. Sample Size
We used an expected standard deviation of ~10 min. day 1 in MVPA
based on data from adults with DS who participated in a recently
completed weight management trial (DK83538, PI Donnelly) for our
sample size estimates. A proposed sample size 32 participants in both the
RH and RL groups will provide a 99% confidence for the estimation of
mean total daily MVPA (�5 min) at each timepoint (baseline, 3, 6, 9 and
12 mos) A proposed sample of 16 participants in the UC group will
provide 94% confidence for the estimation of total daily MVPA (�5 min)
at each time point. Based on our preliminary data, we expect the
6
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maximum likelihood (FIML) estimation in the modeling, which does not
discard participants who dropped out but utilizes all available data from
their partial measurements, thereby producing unbiased parameter es
timates and smallest possible standard errors.

We included low (1 session/wk.) and high frequency (3 sessions/
wk.) group MVPA for 3 reasons. First, 1 group MVPA session/wk. has the
potential to improve total weekly MVPA. Engaging in small amounts of
structured exercise, even acute exercise, has been shown to improve
quality of life [98,99], cardiovascular fitness [100,101], and exercise
self-efficacy [102,103]. Participants in both the RL and RH arms will be
asked to complete weekly homework assignments to increase MVPA in
addition to that delivered in group sessions. Access to recordings of
group sessions delivered to the iPad, weekly education and support, and
provision of a Fitbit for self-monitoring will assist participants with
completing homework assignments. Therefore, participants in the 1
session/wk. arm have the potential to increase MVPA sufficient to
improve meaningful health related outcomes. Second, if effective, de
livery of 1 session/wk. decreases the burden and cost associated with
delivering multiple group MVPA sessions/wk. which may increase the
probability that agencies serving adults with DS would implement and
sustain the intervention. Third, our pilot trial, which included 1 or 2
group MVPA sessions/wk., suggested that 1 group MVPA session/wk.
may impact cognitive function, and also suggested a potential dose
response on both completion of MVPA outside group sessions, and on
changes cognitive function(16). Thus, we included a 3 session/wk. arm
to potentially provide a greater separation in MVPA between arms to
further examine these dose response associations.
Design and methodologic strengths of this trial include: 1) Ran
domized design to groups with concealed allocation of group assign
ments. 2) Adequate sample size to address the aims 3) Strategies to
ensure the recruitment of sufficient participants to achieve our desired
sample size. 4) Retention/incentive strategies to reduce loss to followup. 5) The use of a theory-based intervention delivered by trained
health educators. 6) Review of recordings of all scheduled exercise and
individual support meetings to ensure intervention fidelity. 7) Assess
ments completed by trained staff blind to intervention arm. 8) Evalua
tion of staff inter-rater reliability for all assessments (2–3 times/yr.). 9)
Exit interviews with participants and caregivers to obtain information
for improving and/or implementing the intervention.
Strategies for promoting healthy brain aging and preventing/delay
ing AD are needed in adults with DS, a population at high risk of
developing AD. The development of effective and sustainable inter
vention strategies to increase MVPA in adults with DS may improve
cognitive function and prevent or delay AD. This trial will determine the
feasibility and potential efficacy of remotely delivered group MVPA
delivered at two different frequencies to increase daily MVPA, relative to
a usual care control. This early stage clinical trial will inform and
advance the design of a subsequent late stage clinical trial while
providing important data regarding the effect of MVPA on cognition and
measures of brain health related to development of AD in adults with DS.

3. Discussion
Pathology associated with AD develops in the majority of adults with
DS beginning at ~ age 30 [3,4]. The cumulative incidence of dementia
in adults with DS is in excess of 90% by age 65 [83], and is one of the
main causes of death in individuals with DS [84]. The cause of high rates
of AD in adults with DS is unclear. However, it is suspected that the
additional copy of the amyloid precursor protein results in
over-production of amyloid-beta (Aβ) which accelerates downstream
neurodegeneration, plaque deposition, and early development of
AD-like pathology in individuals with DS [4,85]. Research suggests that
deposition of Aβ occurs decades earlier in adults with DS compared with
typically developed adults who generally develop AD symptoms later in
life [86,87]. For example, in a study of 29 individuals with DS, ranging
in age from 3 to 73 yrs. Aβ deposition was detected as early as age 12 and
was present in all subjects age 31 or older [12]. The initial symptoms of
AD in adults with DS are deficits in executive function and features of
frontotemporal dementia compared with typically developed adults
where deficits in the hippocampus (episodic memory) are the earliest
signs of AD [12–16]. Thus, strategies for the prevention of AD may differ
between typically developed adults and adults with DS(4) thus trial
specific to adults with DS are warranted.
Research suggests that increased MVPA may be effective in main
taining components of cognition, including attention, memory, and ex
ecutive function in typically developed adults with AD [5,7,8,88–90]. In
addition to cognitive benefits, research in typically developed adults
suggests that increased MVPA may prevent or delay the onset of AD by
increasing hippocampal volume, improving cerebral perfusion, facili
tating neurogenesis and synaptogenesis, and favorably influencing
pathological processes related to AD such as diminishing Aβ accumu
lation [29,42–45]. In adults with DS, research has demonstrated the
potential for acute or short-term (�12 wks) MVPA to improve cognition.
In addition to the potential benefits related to cognition and brain
health, increased MVPA in individuals with DS has been associated with
decreased body weight [91], improved cardiovascular fitness [92,93],
and improved muscular strength and endurance [94,95].
There is virtually no information regarding the effectiveness of
intervention strategies designed to increase MVPA in adults with DS.
Adults with DS face challenges to engaging in MVPA including not
enjoying being active on their own, being self-conscious about partici
pating in physical activity with their typically developing peers, and
dependence on caregivers for transportation to a gym or community
center to participate in physical activity [14,15]. Our experimental
intervention, which includes group MVPA for adults with DS delivered
to their home via video conferencing, eliminates these barriers. The
group format also allows interaction between participants which has the
potential to increase accountability, social support, and rapport in a
group with a high potential for social isolation.
Increased MVPA has significant health benefits in adults with DS
[11–13,96]. Therefore, we considered it unethical to randomize par
ticipants to a non-active control. Our UC arm provides written materials,
includes a physical activity tracker for self-monitoring (Fitbit), and
provides individual education/support from a trained health educator
delivered by video conferencing (FaceTime®). FaceTime® delivery
eliminates the travel barrier as most adults with DS are unable to drive.
This approach has been well received by participants in our on-going
weight management intervention in adults with IDD [97]. We believe
using UC instead of a traditional non-active control allows for partici
pants in all intervention arms to have a chance at success and will
provide data to which changes in MVPA in the 2 other intervention arms
can be compared.
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